These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
141 related items for PubMed ID: 2051170
21. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse: an in vivo electrochemical study. Gerhardt G, Rose G, Strömberg I, Conboy G, Olson L, Jonsson G, Hoffer B. J Pharmacol Exp Ther; 1985 Oct; 235(1):259-65. PubMed ID: 2864435 [Abstract] [Full Text] [Related]
22. Rapid and differential losses of in vivo dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice. Kilbourn MR, Kuszpit K, Sherman P. Synapse; 2000 Mar 15; 35(4):250-5. PubMed ID: 10657034 [Abstract] [Full Text] [Related]
23. Studies on the neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: inhibition of NAD-linked substrate oxidation by its metabolite, 1-methyl-4-phenylpyridinium. Vyas I, Heikkila RE, Nicklas WJ. J Neurochem; 1986 May 15; 46(5):1501-7. PubMed ID: 3485701 [Abstract] [Full Text] [Related]
24. Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a radical scavenger, prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the substantia nigra but not the striatum. Kawasaki T, Ishihara K, Ago Y, Baba A, Matsuda T. J Pharmacol Exp Ther; 2007 Jul 15; 322(1):274-81. PubMed ID: 17429058 [Abstract] [Full Text] [Related]
26. Interleukine-1beta and interleukine-6 levels in striatum and other brain structures after MPTP treatment: influence of behavioral lateralization. Shen YQ, Hebert G, Lin LY, Luo YL, Moze E, Li KS, Neveu PJ. J Neuroimmunol; 2005 Jan 15; 158(1-2):14-25. PubMed ID: 15589033 [Abstract] [Full Text] [Related]
27. Alterations in striatal and extrastriatal D-1 and D-2 dopamine receptors in the MPTP-treated common marmoset: an autoradiographic study. Gnanalingham KK, Smith LA, Hunter AJ, Jenner P, Marsden CD. Synapse; 1993 Jun 15; 14(2):184-94. PubMed ID: 8332947 [Abstract] [Full Text] [Related]
28. Decreased Mcl-1 protein level in the striatum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice. Lu E, Sarkar S, Raymick J, Paule MG, Gu Q. Brain Res; 2018 Jan 01; 1678():432-439. PubMed ID: 29158176 [Abstract] [Full Text] [Related]
29. Meloxicam ameliorates motor dysfunction and dopaminergic neurodegeneration by maintaining Akt-signaling in a mouse Parkinson's disease model. Tasaki Y, Yamamoto J, Omura T, Sakaguchi T, Kimura N, Ohtaki K, Ono T, Suno M, Asari M, Ohkubo T, Noda T, Awaya T, Shimizu K, Matsubara K. Neurosci Lett; 2012 Jul 11; 521(1):15-9. PubMed ID: 22617635 [Abstract] [Full Text] [Related]
30. Inhibition of mitochondrial respiration by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mouse brain in vivo. Mizuno Y, Suzuki K, Sone N, Saitoh T. Neurosci Lett; 1988 Sep 12; 91(3):349-53. PubMed ID: 3141846 [Abstract] [Full Text] [Related]
31. (+)MK-801 does not prevent MPTP-induced loss of nigral neurons in mice. Chan P, Di Monte DA, Langston JW, Janson AM. J Pharmacol Exp Ther; 1997 Jan 12; 280(1):439-46. PubMed ID: 8996226 [Abstract] [Full Text] [Related]
32. Acute Restraint Stress Augments 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Neurotoxicity via Increased Toxin Uptake into the Brain in C57BL/6 Mice. Mitsumoto Y, Mori A. Neurosci Bull; 2018 Oct 12; 34(5):849-853. PubMed ID: 29987518 [Abstract] [Full Text] [Related]
33. The MAP kinase cascade is activated prior to the induction of gliosis in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of dopaminergic neurotoxicity. O'Callaghan JP, Martin PM, Mass MJ. Ann N Y Acad Sci; 1998 May 30; 844():40-9. PubMed ID: 9668663 [Abstract] [Full Text] [Related]
34. Mitochondrial toxins in models of neurodegenerative diseases. II: Elevated zif268 transcription and independent temporal regulation of striatal D1 and D2 receptor mRNAs and D1 and D2 receptor-binding sites in C57BL/6 mice during MPTP treatment. Smith TS, Trimmer PA, Khan SM, Tinklepaugh DL, Bennett JP. Brain Res; 1997 Aug 15; 765(2):189-97. PubMed ID: 9313891 [Abstract] [Full Text] [Related]
35. The effect of diethyldithiocarbamate on the biodisposition of MPTP: an explanation for enhanced neurotoxicity. Irwin I, Wu EY, DeLanney LE, Trevor A, Langston JW. Eur J Pharmacol; 1987 Sep 11; 141(2):209-17. PubMed ID: 2824216 [Abstract] [Full Text] [Related]
36. Epidermal growth factor enhances striatal dopaminergic parameters in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mouse. Hadjiconstantinou M, Fitkin JG, Dalia A, Neff NH. J Neurochem; 1991 Aug 11; 57(2):479-82. PubMed ID: 1677029 [Abstract] [Full Text] [Related]
37. Short- and long-term changes in striatal and extrastriatal dopamine uptake sites in the MPTP-treated common marmoset. Gnanalingham KK, Milkowski NA, Smith LA, Hunter AJ, Jenner P, Marsden CD. Eur J Pharmacol; 1995 Apr 24; 277(2-3):235-41. PubMed ID: 7493614 [Abstract] [Full Text] [Related]
38. Melatonin is protective against MPTP-induced striatal and hippocampal lesions. Acuña-Castroviejo D, Coto-Montes A, Gaia Monti M, Ortiz GG, Reiter RJ. Life Sci; 1997 Apr 24; 60(2):PL23-9. PubMed ID: 9000122 [Abstract] [Full Text] [Related]
39. Astrocytic responses to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in cat and mouse brain. Schneider JS, Denaro FJ. J Neuropathol Exp Neurol; 1988 Jul 24; 47(4):452-8. PubMed ID: 2898510 [Abstract] [Full Text] [Related]
40. Attenuation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity by the novel selective dopamine D3-receptor partial agonist FAUC 329 predominantly in the nucleus accumbens of mice. Boeckler F, Leng A, Mura A, Bettinetti L, Feldon J, Gmeiner P, Ferger B. Biochem Pharmacol; 2003 Sep 15; 66(6):1025-32. PubMed ID: 12963489 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]